To the editor
In her News and Views1, Steeg called into question “the simple, elegant idea of stopping tumors with angiogenesis inhibitors,” because of her presumption that “such inhibitors, by depriving tumors of oxygen, could have an unintended effect: promotion of metastasis.” This opinion is based on the insightful, but misinterpreted, data in a recent report by Pennacchietti et al.2, who showed that hypoxia promotes invasive growth of tumor cells by transcriptional activation of the met proto-oncogene. From these data, Pennacchietti et al. speculated that angiogenesis inhibitors could increase tumor invasion and spread. In another News and Views, Botarro and Liotta made a similar speculation3.
The preponderance of preclinical and clinical evidence contradicts this perception, however. First, the formation of metastases is suppressed by a variety of angiogenesis inhibitors in animal models4,5 including VEGF antagonists4,5, TNP-470 (ref. 6), endostatin7 and interferon-α8. Second, even in the rare cases where an angiogenesis inhibitor seems to 'stimulate' formation of metastases from a primary tumor9, this effect was subsequently explained by regression of the primary tumor, resulting in loss of an angiogenesis inhibitor generated by that tumor. This is similar to the rapid appearance of metastases after certain types of primary tumors are surgically removed10 or caused to regress by ionizing radiation, resulting in decreased circulating levels of angiostatin11. Third, an increase in metastases has not been observed in large clinical trials of angiogenesis inhibitors. For example, in a recent randomized, placebo-controlled, blinded clinical trial of more than 900 patients with colorectal cancer, disease progression—defined as the growth of tumors or the emergence of new metastases—was significantly prolonged by the addition of the VEGF inhibitor Avastin to conventional chemotherapy (H. Hurwitz, personal communication). In addition, there has been no evidence of promotion of metastases in the thousands of patients treated to date with thalidomide12, interferon-α or cyclooxygenase-2 inhibitors13, compounds that have a range of antiangiogenic activities in different tumors.
Steeg also emphasizes that p53-null tumor cells are relatively more resistant to hypoxia than are tumor cells with wild-type p53, as reported by Yu et al.14 Nevertheless, it has been shown that antiangiogenic therapy can successfully inhibit the growth of p53-null tumors, as we previously discussed15. Hypoxia in a tumor induces a number of compensatory mechanisms, including the induction of proangiogenic genes through the hypoxia-inducible factor (HIF)-lα pathway and potential increases in tumor cell invasiveness and that these mechanisms merit further investigation. Some have assumed that these compensatory pathways would be the Achilles' heel of antiangiogenic therapy. But in fact, antiangiogenic therapy in preclinical and clinical studies continues to demonstrate that growth of primary tumors and their metastases can be inhibited in the presence of activation of proangiogenic pathways. Angiogenesis inhibitors do far more than simply “deprive a tumor of oxygen.” They inhibit vascular leakage in a tumor, inhibit endothelial nitric oxide synthase, downregulate expression of HIF-lα, upregulate expression of an inhibitor of HIF-lα, upregulate thrombospondin (a potent endogenous angiogenesis inhibitor) and downregulate plasmin production, to name just a few activities16,17. In other words, certain angiogenesis inhibitors can counteract the compensatory pathways that tumors use in response to hypoxia. Taken together, these reports provide strong evidence that the use of angiogenesis inhibitors, alone or in combinations, does not promote, and can in fact inhibit, metastasis. This evidence supports the clinical testing of angiogenesis inhibitors for the treatment of both primary tumors and metastases.
See Reply to “Angiogenesis inhibitors and hypoxia” by Patricia S. Steeg
References
Steeg, P.S. Angiogenesis inhibitors: motivators of metastasis? Nat. Med. 9, 822–823 (2003).
Pennacchietti, S. et al. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 3, 347–361 (2003).
Bottaro, D.P. & Liotta, L.A. Out of air is not out of action. Nature 423, 593–595 (2003).
Shaheen, R.M. et al. Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastases and induces tumor and endothelial cell apoptosis. Cancer Res. 59, 5412–5416 (1999).
Drevs, J. et al. Effects of PTK787/ZK222584, a specific inhibitor of vascular endothelial growth factor tyrosine kinases, on primary tumor metastasis, vessel density, and blood flow in a murine renal cell carcinoma model. Cancer Res. 60, 4819–4824 (2000).
Inoue, K. et al. Frequent administration of angiogenesis inhibitor TNP-470 (AGM-1470) at an optimal biological dose inhibits tumor growth and metastasis of metastatic human transitional cell carcinoma in the urinary bladder. Clin. Cancer Res. 8, 2389–2398 (2002).
Sauter, B.V. et al. Adenovirus-mediated gene transfer of endostatin in vivo results in high level of transgene expression and inhibition of tumor growth and metastases. Proc. Natl. Acad. Sci. USA 97, 4802–4807 (2002).
Wang, L. et al. Mechanism of interferon alpha on inhibition of metastasis and angiogenesis of hepatocellular carcinoma after curative resection in nude mice. J. Gastrointest. Surg. 7, 587–594 (2003).
Kaban, L. et al. Antiangiogenic therapy with interferon alpha for giant cell lesions of the jaws. J. Oral Maxillofac. Surg. 60, 1103–1111 (2002).
Holmgren, L., O'Reilly, M.S. & Folkman, J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat. Med. 1, 149–153 (1995).
Camphausen, K. et al. Radiation therapy to a primary tumor accelerates metastatic growth in mice. Cancer Res. 61, 2207–2211 (2001).
Weber, D. et al. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J. Clin. Oncol. 21, 16–19 (2003).
Steinbach, G. et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med. 342, 1946–1952 (2000).
Yu, J., Rak, J., Coomber, B., Hicklin, D. & Kerbel, R. Effect of tumor response to p53 status on tumor response to antiangiogenic therapy. Science 295, 1526–1528 (2002).
Browder, T. et al. Antiangiogenic therapy and p53. Science 297, 471 (2002).
Mabjeesh, N.J. et al. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 3, 363–375 (2003).
Folkman, J. & Kalluri, R. Tumor angiogenesis. in Cancer Medicine, 6th edn. (eds. Kufe, D.W. et al.) 161–194 (B.C. Decker, Hamilton, Ontario, 2003).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Kieran, M., Folkman, J. & Heymach, J. Angiogenesis inhibitors and hypoxia. Nat Med 9, 1104 (2003). https://doi.org/10.1038/nm0903-1104a
Issue Date:
DOI: https://doi.org/10.1038/nm0903-1104a
This article is cited by
-
Uterine fibroids are characterized by an impaired antioxidant cellular system: potential role of hypoxia in the pathophysiology of uterine fibroids
Journal of Assisted Reproduction and Genetics (2013)
-
RETRACTED ARTICLE: Inhibition of Tumor Angiogenesis by Tumstatin: Insights into Signaling Mechanisms and Implications in Cancer Regression
Pharmaceutical Research (2008)
-
Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system
Nature (2005)